Sinan Tanyolac

Prof. Sinan Tanyolac

Istanbul Biruni University
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Eusebio ChiefariEusebio Chiefari
Eusebio Chiefari
Maria MirabelliMaria Mirabelli
Maria Mirabelli
Sandro La VigneraSandro La Vignera
Sandro La Vignera
Sinan TanyolacSinan Tanyolac
Sinan Tanyolac
Daniela P. FotiDaniela P. Foti
Daniela P. Foti
Antonio BrunettiAntonio Brunetti
Antonio Brunetti
Insulin resistance (IR) is a condition which refers to individuals whose cells and tissues become insensitive to the peptide hormone, insulin. Over the recent years, a wealth of data has made it clear that a synergistic relationship exists between IR, type 2 diabetes mellitus, and cancer. Although the underlying mechanism(s) for this association remain unclear, it is well established that hyperinsulinemia, a hallmark of IR, may play a role in tumorigenesis. On the other hand, IR is strongly associated with visceral adiposity dysfunction and systemic inflammation, two conditions which favor the establishment of a pro-tumorigenic environment. Similarly, epigenetic modifications, such as DNA methylation, histone modifications, and non-coding RNA, in IR states, have been often associated with tumorigenesis in numerous types of human cancer. In addition to these observations, it is also broadly accepted that gut microbiota may play an intriguing role in the development of IR-related diseases, including type 2 diabetes and cancer, whereas potential chemopreventive properties have been attributed to some of the most commonly used antidiabetic medications. Herein we provide a concise overview of the most recent literature in this field and discuss how different but interrelated molecular pathways may impact on tumor development.

2 March 2011 in JAMA
Verified
Journal Article
Open access
PDF file
Eusebio ChiefariEusebio Chiefari
Eusebio Chiefari
Sinan TanyolacSinan Tanyolac
Sinan Tanyolac
FPFrancesco Paonessa
Francesco Paonessa
CPClive R. Pullinger
Clive R. Pullinger
CCCarmelo Capula
Carmelo Capula
Antonio BrunettiAntonio Brunetti
Antonio Brunetti
Type 2 diabetes mellitus (DM) is a common metabolic disorder that affects nearly 250 million people worldwide,1,2 and is associated with major diabetes-related complications, including retinopathy, nephropathy, neuropathy, and cardiovascular disease.3 Type 2 DM is a complex disease in which both genetic and environmental factors interact to produce hyperglycemia.4,5 Insulin resistance in muscle, liver, and adipose tissue is a major feature of most patients with type 2 DM,6 making these tissues resistant to both endogenous and exogenous insulin.6

1 August 2011 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
ABAmélie Bonnefond
Amélie Bonnefond
GLGwen Lomberk
Gwen Lomberk
NBNavtej Buttar
Navtej Buttar
KBKanetee Busiah
Kanetee Busiah
EVEmmanuel Vaillant
Emmanuel Vaillant
RURaul A. Urrutia
Raul A. Urrutia
Krüppel-like transcription factors (KLFs) have elicited significant attention because of their regulation of essential biochemical pathways and, more recently, because of their fundamental role in the mechanisms of human diseases. Neonatal diabetes mellitus is a monogenic disorder with primary alterations in insulin secretion. We here describe a key biochemical mechanism that underlies neonatal diabetes mellitus insulin biosynthesis impairment, namely a homozygous mutation within the insulin gene (INS) promoter, c.-331C>G, which affects a novel KLF-binding site. The combination of careful expression profiling, electromobility shift assays, reporter experiments, and chromatin immunoprecipitation demonstrates that, among 16 different KLF proteins tested, KLF11 is the most reliable activator of this site. Congruently, the c.-331C>G INS mutation fails to bind KLF11, thus inhibiting activation by this transcription factor. Klf11−/− mice recapitulate the disruption in insulin production and blood levels observed in patients. Thus, these data demonstrate an important role for KLF11 in the regulation of INS transcription via the novel c.-331 KLF site. Lastly, our screening data raised the possibility that other members of the KLF family may also regulate this promoter under distinct, yet unidentified, cellular contexts. Collectively, this study underscores a key role for KLF proteins in biochemical mechanisms of human diseases, in particular, early infancy onset diabetes mellitus.

Maria MirabelliMaria Mirabelli
Maria Mirabelli
Eusebio ChiefariEusebio Chiefari
Eusebio Chiefari
PCPatrizia Caroleo
Patrizia Caroleo
BABiagio Arcidiacono
Biagio Arcidiacono
DCDomenica Maria Corigliano
Domenica Maria Corigliano
Antonio BrunettiAntonio Brunetti
Antonio Brunetti
Background: Liraglutide is the first glucagon-like peptide-1 receptor agonist (GLP-1 RA) based on the human GLP-1 sequence, with potential weight loss benefits, approved for the treatment of type 2 diabetes (T2D) mellitus. Herein, we aimed to assess the 5-year effectiveness of Liraglutide in the management of weight and glycometabolic control in a Southern Italian cohort of overweight/obese T2D patients, who were naïve to GLP-1 RAs. Patients and Methods: Forty overweight or obese patients treated with Liraglutide at doses up to 1.8 mg/day, in combination with one or more oral antidiabetic agents, were retrospectively assessed at baseline, during, and after 60 months of continuous therapy. Results: After 5 years of Liraglutide treatment, body weight decreased from 92.1 ± 20.5 kg to 87.3 ± 20.0 Kg (p < 0.001), with a mean reduction of 5.0 ± 7.0 Kg and a body mass index (BMI) decrement of −2.0 ± 3.1 Kg/m2. On Spearman’s univariate analysis, change in body weight was correlated with female gender and baseline BMI. Hemoglobin A1c (HbA1c) decreased from 7.9 ± 0.9% at baseline to 7.0 ± 0.7% at the end of the study period (p < 0.001), followed by a significant reduction in fasting plasma glucose. No significant differences emerged in other biochemical parameters, despite a trend toward improvement in lipid profile. Notwithstanding encouraging effects on several markers of cardiovascular disease (CVD), increments in the 5- and 10-year risk for the first atherosclerotic cardiovascular event were documented, as four incident cases of myocardial infarction. Conclusions: Prolonging treatment with Liraglutide can lead to durable benefits in relation to weight and glycemic control, with a greater impact on women. These results extend and corroborate previous observations, suggesting that gender per se may modulate the response to Liraglutide. Despite favorable effects on some established CVD risks factors, the long-term role of Liraglutide in primary prevention of CVD in patients with T2D remains controversial.

20 March 2013 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Eusebio ChiefariEusebio Chiefari
Eusebio Chiefari
Sinan TanyolacSinan Tanyolac
Sinan Tanyolac
SIStefania Iiritano
Stefania Iiritano
ASAngela Sciacqua
Angela Sciacqua
CCCarmelo Capula
Carmelo Capula
Antonio BrunettiAntonio Brunetti
Antonio Brunetti
The metabolic syndrome (MetS) is a common disorder, where systemic insulin-resistance is associated with increased risk for type 2 diabetes (T2D) and cardiovascular disease. Identifying genetic traits influencing risk and progression of MetS is important. We and others previously reported a functional HMGA1 gene variant, rs146052672, predisposing to T2D. Here we investigated the association of rs146052672 variant with MetS and related components. In a case-control study from Italy and Turkey, increased risk of MetS was seen among carriers of the HMGA1 variant. In the larger Italian cohort, this variant positively correlated with BMI, hyperglycemia and insulin-resistance, and negatively correlated with serum HDL-cholesterol. Association between rs146052672 variant and MetS occurred independently of T2D, indicating that HMGA1 gene defects play a pathogenetic role in MetS and other insulin-resistance-related conditions. Overall, our results indicate that the rs146052672 variant represents an early predictive marker of MetS, as well as a predictive tool for therapy.

1 February 2014 in Metabolic Syndrome and Related Disorders
Verified
Journal Article
Closed access
CPClive R. Pullinger
Clive R. Pullinger
IGIra D. Goldfine
Ira D. Goldfine
Sinan TanyolacSinan Tanyolac
Sinan Tanyolac
IMIrina Movsesyan
Irina Movsesyan
MFMark Faynboym
Mark Faynboym
JKJohn P. Kane
John P. Kane
High-mobility group AT-hook 1 (HMGA1) is an important regulator of the insulin receptor gene. We have previously shown in three populations of white European ancestry that the HMGA1 gene variant rs146052672 (also designated IVS5-13insC) is associated with type 2 diabetes mellitus (T2DM). The aim of this study was to measure the frequency of this variant and to determine the degree of the association with T2DM and other features of the metabolic syndrome in a replication cohort of Hispanic Americans. This was a retrospective cohort study of well-characterized Hispanic-American participants analyzed in the Genomic Resource in Atherosclerosis (GRA) (Cardiovascular Research Institute, University of California, San Francisco). A total of 1144 individuals were studied, 320 of whom had T2DM. We examined associations of the rs146052672 SNP with T2DM, plasma lipids, lipoproteins, and body mass index (BMI). In this Hispanic-American cohort, the HMGA1 rs146052672 minor allele (C-insertion) frequency (MAF) was 21.4% with a carrier frequency of 37.4%, considerably higher than we previously observed among GRA white Europeans (MAF 3.1%). The prevalence of the IVS5-13insC variant was significantly higher in those with T2DM compared to controls [42.2% vs. 35.5%; odds ratio (OR) 1.44 95% confidence interval (CI) 1.09-1.90, P=0.011). The variant was also associated with BMI (positively, P=0.045) and plasma high-density lipoprotein cholesterol (HDL-C) (negatively, P=0.047). As we saw previously among white Europeans, a functional HMGA1 variant was associated with T2DM in individuals of Hispanic-American ethnicity and was present at a much higher frequency.